Valneva SE
VALN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001836564
No open-market purchases or sales by Valneva SE insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $19.8M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Valneva SE changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 18 | 18 | 0 |
| Shares | 4.52M | 5.27M | +752.5K (+16.6%) |
| Value | $25.6M | $64.3M | +$38.7M (+151.3%) |
New holders (3)
Institutions that held Valneva SE at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 31,211 | $380.8K | 0.00% |
| JPMorgan Chase & Co | 10,179 | $124.2K | 0.00% |
| Barclays PLC | 196 | $2.39K | 0.00% |
Sold out (3)
Institutions that held Valneva SE at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Marex Group plc | 11,300 | $64.1K |
| Ridgewood Investments LLC | 550 | $3.12K |
| Raymond James Financial Inc | 41 | $232 |